Annexon Earnings Call Transcripts
Fiscal Year 2026
-
2026 is set to be a milestone year, with anticipated regulatory filings and pivotal data readouts for late-stage programs in GBS, GA, and ANX1502. Vonaprument’s differentiated C1q-targeting approach in GA is advancing through a robust phase III trial, while GBS and ANX1502 programs are progressing toward key regulatory and clinical milestones.
-
C1q inhibition offers a novel, upstream approach to preserving vision in GA by protecting photoreceptors, with phase II data showing strong functional and structural benefits and a favorable safety profile. The phase III ARCHER II trial is fully enrolled, highly powered, and aligned with regulators, with results expected in Q4.
-
The company is advancing three late-stage programs targeting neuroinflammatory diseases, with pivotal data and regulatory filings expected in GA and GBS. Strong clinical results, a differentiated mechanism, and robust commercial planning position the pipeline for significant value creation over the next year.
-
Late-stage immunotherapy programs targeting neuroinflammatory diseases are set for pivotal milestones in 2026, including phase III data for ANX007 in geographic atrophy and regulatory filings for ANX005 in Guillain-Barré syndrome. ANX1502 advances as the first oral C1 inhibitor for autoimmune conditions.
Fiscal Year 2025
-
The company is advancing a differentiated complement platform with late-stage programs in GBS and GA, both targeting major regulatory milestones in 2026. GBS data show strong efficacy and safety, while the GA program aims for vision preservation. An oral complement program is also progressing, with proof-of-concept data expected in 2026.
-
The company is advancing first-in-class complement pathway inhibitors, with ANX005 showing strong phase III results in GBS and outperforming IVIG in key outcomes. Regulatory filings are on track, with EMA submission planned for Q1 2026 and pivotal data for ANX007 in GA expected next year.
-
Pioneering therapies in GBS, GA, and small molecule complement inhibition are advancing, with robust clinical data, strong regulatory engagement, and clear commercialization strategies. GBS filings are targeted for Q1 2026 in Europe, and GA phase III data is expected in 2026.
-
At the H.C. Wainwright Ophthalmology Conference, Annexon highlighted its C1q inhibitor programs, including positive phase III results in Guillain-Barré syndrome and vision-preserving effects in dry AMD. The fully enrolled phase III ARCHER II trial for Vonaprument expects top-line data in 2026.
-
Late-stage complement pathway therapies are advancing, with a pivotal GBS program showing strong efficacy and regulatory progress toward BLA filing in the second half of the year. Market access strategies, including U.S. and EU filings and proactive Western patient studies, are underway. Small molecule and geographic atrophy programs are also progressing, with key data readouts expected in 2025.
-
Key programs in GBS and GA are advancing, with GBS preparing for BLA submission and GA phase 3 enrollment on track. ANX005 shows strong efficacy and safety in GBS, while ANX007 leads in vision preservation for GA. Cash runway extends into 2026.
-
The conference highlighted a robust pipeline targeting complement-mediated diseases, with ANX005 for GBS and ANX007 for geographic atrophy showing strong clinical progress and commercial potential. ANX1502, an oral inhibitor, is advancing with proof-of-concept data expected soon.
Fiscal Year 2024
-
Real-world evidence shows ANX005 delivers rapid, significant improvements in muscle strength and disability for GBS patients compared to IVIG or plasma exchange, with a favorable safety profile. Experts expect ANX005 to become the new standard of care, and regulatory submission is planned for 2025.
-
The company is advancing therapies targeting the classical complement pathway, with a positive GBS Phase III study, a promising oral small molecule program, and a global Phase III in geographic atrophy. Regulatory filings and key data readouts are expected in 2025 and 2026.
-
The conference highlighted robust phase III data for GBS, with ANX005 showing rapid, durable benefits and a favorable safety profile. Real-world evidence and IVIG comparison data are expected by year-end, supporting a 2025 BLA submission. The pipeline also advances in geographic atrophy and oral complement inhibition.
-
The company presented robust phase III GBS data showing rapid, significant patient recovery and outlined a regulatory path leveraging global datasets. The GA program received PRIME designation in the EU for unique vision preservation, while the oral small molecule pipeline advances in autoimmune diseases.
-
Positive phase III results for ANX005 in GBS showed significant improvements in disability, muscle strength, and time to recovery versus placebo, with a strong safety profile. The single-dose therapy is poised to become the first targeted, FDA-approved treatment for GBS, with regulatory submission planned for 2025.